Targeting MCL ‐1 and MAPK overcomes venetoclax resistance in FLT3 ‐ ITD‐ positive AML cells harbouring activating PTPN11 ( SHP ‐2) mutations
British Journal of Haematology · 2026-03 · 208 (3) · 905-915
DOI: 10.1111/bjh.70344 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 29.01.2026. Verfasst von Maximilian Fleischmann und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Clinic for Internal Medicine II, Comprehensive Cancer Center Central Germany-Campus Jena, University H…. Hauptthemen laut MEDLINE: Myeloid Cell Leukemia Sequence 1 Protein, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Jena, José Carreras Leukämie-Stiftung.
Abstract (Originalsprache)
Venetoclax (VEN)‐based therapies have improved the treatment of acute myeloid leukaemia (AML); however, the emergence of resistance remains a major limitation. Mutations in protein tyrosine phosphatase (PTP) non‐receptor type 11 (PTPN11) and FMS like tyrosine kinase 3 with internal tandem duplication (FLT3‐ITD) are common in resistant patients and are linked to activation of mitogen‐activated protein kinase (MAPK) signalling and increased expression of anti‐apoptotic proteins such as myeloid cell leukaemia 1 (MCL‐1) and b‐cell lymphoma‐extra large (BCL(x)L). Murine Ba/F3 cells with different FLT3‐ITD variants were lentiviral transduced to express either wild‐type PTPN11 (Src‐homology 2 containing PTP) or the activating PTPN11‐E76K mutation. Cells were treated with VEN, the MCL‐1 inhibitor S63845 and the mitogen‐activated protein kinase (MEK) inhibitor trametinib (TRA), alone or in combination. Additionally, primary AML samples were examined for drug sensitivity and protein expression profiles. Cells expressing PTPN11‐E76K showed marked resistance to VEN, coinciding with sustained extracellular signal‐regulated kinase activation and elevated MCL‐1 and BCL(x)L levels. Combining VEN with MCL‐1 inhibition significantly increased apoptosis. Co‐treatment with TRA provided substantial synergistic benefits while yielding a more modest benefit in PTPN11‐E76K‐mutant cells. Both PTPN11 and FLT3 mutations confer resistance in AML, making them key factors in identifying high‐risk patients. The presented results highlight the role of MAPK‐driven MCL‐1 and BCL(x)L expression, which mediates VEN resistance. While dual inhibition of B‐cell lymphoma 2 and MCL‐1 is already effective, additional MEK inhibition may further improve outcomes in PTPN11‐mutated AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Medical Oncology, Clinic for Internal Medicine II, Comprehensive Cancer Center Central Germany-Campus Jena, University Hospital Jena, Jena, Germany.
- Institute of Human Genetics, University Hospital Jena, Jena, Germany.
- Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany.
- Leibniz Institute on Aging-Fritz-Lipmann-Institute, Jena, Germany.
- Institute of Molecular Cell Biology, University Hospital Jena, Jena, Germany.
ORCID-Profile: Maximilian Fleischmann, Ulf Schnetzke
Förderung
- Deutsche Forschungsgemeinschaft
- Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Jena
- José Carreras Leukämie-Stiftung
Zitieren
APA
Fleischmann, M., Hansen, O., Voigtländer, D., Bechwar, J., Schwietzer, L. J., Bahr, S., Schnetzke, U., Fischer, M., Heidel, F. H., Schnöder, T. M., Müller, J. P., Hochhaus, A., & Scholl, S. (2026). Targeting MCL ‐1 and MAPK overcomes venetoclax resistance in FLT3 ‐ ITD‐ positive AML cells harbouring activating PTPN11 ( SHP ‐2) mutations. British Journal of Haematology, 208(3), 905-915. https://doi.org/10.1111/bjh.70344
Vancouver
Fleischmann M, Hansen O, Voigtländer D, Bechwar J, Schwietzer LJ, Bahr S, et al. Targeting MCL ‐1 and MAPK overcomes venetoclax resistance in FLT3 ‐ ITD‐ positive AML cells harbouring activating PTPN11 ( SHP ‐2) mutations. British Journal of Haematology. 2026;208(3):905-915. doi:10.1111/bjh.70344
BibTeX
@article{Fleischmann2026,
author = {Fleischmann, Maximilian and Hansen, Ole and Voigtländer, Diana and Bechwar, Julia and Schwietzer, Lenny-Joseph and Bahr, Sanja and Schnetzke, Ulf and Fischer, Mike and Heidel, Florian H and Schnöder, Tina M and Müller, Jörg P and Hochhaus, Andreas and Scholl, Sebastian},
title = {Targeting MCL ‐1 and MAPK overcomes venetoclax resistance in FLT3 ‐ ITD‐ positive AML cells harbouring activating PTPN11 ( SHP ‐2) mutations},
journal = {British Journal of Haematology},
year = {2026},
volume = {208},
number = {3},
pages = {905--915},
doi = {10.1111/bjh.70344}
}
EUVIMED